Patrick P Gleason

Summary

Affiliation: Prime Therapeutics
Country: USA

Publications

  1. ncbi request reprint Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007
    April M Kunze
    Prime Therapeutics, 1305 Corporate Center Drive, Eagan, MN 55121, USA
    J Manag Care Pharm 13:799-806. 2007
  2. ncbi request reprint Health plan utilization and costs of specialty drugs within 4 chronic conditions
    Patrick P Gleason
    Health Outcomes, Prime Therapeutics, LLC, 3101 Canterbury Dr, Minneapolis, MN 55431, USA
    J Manag Care Pharm 19:542-8. 2013
  3. ncbi request reprint Dalfampridine prior authorization program: a cohort study
    Patrick P Gleason
    Prime Therapeutics LLC, Eagan, MN 55121, USA
    J Manag Care Pharm 19:18-25. 2013
  4. ncbi request reprint Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program
    Patrick P Gleason
    Medical and Pharmacy Integration Services, Prime Therapeutics, LLC, Eagan, Minnesota 55121, USA
    Pharmacotherapy 25:924-34. 2005
  5. ncbi request reprint Assessing step-therapy programs:a step in the right direction
    Patrick P Gleason
    Medical and Pharmacy Integration Services, Prime Therapeutics, LLC, Eagan, Minnesota, USA
    J Manag Care Pharm 13:273-5. 2007
  6. ncbi request reprint Telithromycin: the perils of hasty adoption and persistence of off-label prescribing
    Patrick P Gleason
    Prime Therapeutics LLC, Eagan, MN 55121, USA
    J Manag Care Pharm 13:420-5. 2007
  7. ncbi request reprint Association of prescription abandonment with cost share for high-cost specialty pharmacy medications
    Patrick P Gleason
    Prime Therapeutics, 1305 Corporate Center Dr, Eagan, MN 55121, USA
    J Manag Care Pharm 15:648-58. 2009
  8. ncbi request reprint Are incentive-based formularies inversely associated with drug utilization in managed care?
    Patrick P Gleason
    Prime Therapeutics, LLC, Eagan, MN 55121 3497, USA
    Ann Pharmacother 39:339-45. 2005
  9. ncbi request reprint Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers
    Dongmu Zhang
    University of Minnesota, Minneapolis, MN, USA
    J Manag Care Pharm 13:664-76. 2007
  10. ncbi request reprint Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events
    Catherine I Starner
    Prime Therapeutics LLC, Eagan, Minnesota, USA
    J Manag Care Pharm 14:523-31. 2008

Detail Information

Publications19

  1. ncbi request reprint Utilization, cost trends, and member cost-share for self-injectable multiple sclerosis drugs--pharmacy and medical benefit spending from 2004 through 2007
    April M Kunze
    Prime Therapeutics, 1305 Corporate Center Drive, Eagan, MN 55121, USA
    J Manag Care Pharm 13:799-806. 2007
    ..Self-injectable MS drugs are expensive, costing approximately $2,000 per month per patient in 2007...
  2. ncbi request reprint Health plan utilization and costs of specialty drugs within 4 chronic conditions
    Patrick P Gleason
    Health Outcomes, Prime Therapeutics, LLC, 3101 Canterbury Dr, Minneapolis, MN 55431, USA
    J Manag Care Pharm 19:542-8. 2013
    ....
  3. ncbi request reprint Dalfampridine prior authorization program: a cohort study
    Patrick P Gleason
    Prime Therapeutics LLC, Eagan, MN 55121, USA
    J Manag Care Pharm 19:18-25. 2013
    ..To ensure safe and appropriate dalfampridine use, a health plan developed and implemented a 2-phase point-of-sale PA program...
  4. ncbi request reprint Medical and pharmacy expenditures after implementation of a cyclooxygenase-2 inhibitor prior authorization program
    Patrick P Gleason
    Medical and Pharmacy Integration Services, Prime Therapeutics, LLC, Eagan, Minnesota 55121, USA
    Pharmacotherapy 25:924-34. 2005
    ..To evaluate the effects of a cyclooxygenase (COX)-2 inhibitor prior authorization (PA) program on direct medical and pharmacy costs...
  5. ncbi request reprint Assessing step-therapy programs:a step in the right direction
    Patrick P Gleason
    Medical and Pharmacy Integration Services, Prime Therapeutics, LLC, Eagan, Minnesota, USA
    J Manag Care Pharm 13:273-5. 2007
  6. ncbi request reprint Telithromycin: the perils of hasty adoption and persistence of off-label prescribing
    Patrick P Gleason
    Prime Therapeutics LLC, Eagan, MN 55121, USA
    J Manag Care Pharm 13:420-5. 2007
    ..On February 12, 2007, the U.S. Food and Drug Administration (FDA) removed the bacterial sinusitis and ABECB indications and strengthened safety warnings for telithromycin...
  7. ncbi request reprint Association of prescription abandonment with cost share for high-cost specialty pharmacy medications
    Patrick P Gleason
    Prime Therapeutics, 1305 Corporate Center Dr, Eagan, MN 55121, USA
    J Manag Care Pharm 15:648-58. 2009
    ....
  8. ncbi request reprint Are incentive-based formularies inversely associated with drug utilization in managed care?
    Patrick P Gleason
    Prime Therapeutics, LLC, Eagan, MN 55121 3497, USA
    Ann Pharmacother 39:339-45. 2005
    ..To review recent studies comprehensively assessing the impact of incentive-based multitier formularies on pharmaceutical costs and utilization...
  9. ncbi request reprint Relationship of the magnitude of member cost-share and medication persistence with newly initiated renin angiotensin system blockers
    Dongmu Zhang
    University of Minnesota, Minneapolis, MN, USA
    J Manag Care Pharm 13:664-76. 2007
    ..Little is known about the relationship between the magnitude of member cost-sharing and antihypertensive persistence among members newly initiating therapy...
  10. ncbi request reprint Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events
    Catherine I Starner
    Prime Therapeutics LLC, Eagan, Minnesota, USA
    J Manag Care Pharm 14:523-31. 2008
    ....
  11. ncbi request reprint Critical review of prasugrel for formulary decision makers
    Jeremy A Schafer
    Prime Therapeutics, 1305 Corporate Center Drive, Eagan, MN 55121, USA
    J Manag Care Pharm 15:335-43. 2009
    ....
  12. ncbi request reprint Generic drug discount programs: are prescriptions being submitted for pharmacy benefit adjudication?
    Alexandra Tungol
    Prime Therapeutics LLC, 1305 Corporate Center Dr, Eagan, MN 55121, USA
    J Manag Care Pharm 18:690-700. 2012
    ....
  13. doi request reprint Dronedarone: current evidence and future questions
    Jeremy A Schafer
    Prime Therapeutics LLC, Eagan, MN, USA
    Cardiovasc Ther 28:38-47. 2010
    ..Questions remain on the long-term safety, use in patients with heart failure, retreatment after dronedarone or amiodarone failure, and comparative efficacy with a rate control strategy...
  14. ncbi request reprint Rosiglitazone prior authorization safety policy: a cohort study
    Catherine I Starner
    Prime Therapeutics LLC, 1305 Corporate Center Dr, Eagan, MN 55121, USA
    J Manag Care Pharm 18:225-33. 2012
    ..The label for rosiglitazone was revised in November 2007 to include the warning of contraindicated use with nitrates or insulin, creating an opportunity for a PA directed at safe use...
  15. doi request reprint Effect of a retrospective drug utilization review on potentially inappropriate prescribing in the elderly
    Catherine I Starner
    Prime Therapeutics, Eagan, Minnesota, USA
    Am J Geriatr Pharmacother 7:11-9. 2009
    ..Although the literature suggests DAE are associated with negative health outcomes, educational interventions have had a positive impact on inappropriate prescribing...
  16. ncbi request reprint Cholinesterase inhibitor utilization patterns: just because it can be counted does not mean it counts
    Catherine I Starner
    Prime Therapeutics LLC, 1305 Corporate Center Dr, Eagan, MN 55121, USA
    J Manag Care Pharm 14:462-4. 2008
  17. ncbi request reprint Formulary review of 2 new biologic agents: tocilizumab for rheumatoid arthritis and ustekinumab for plaque psoriasis
    Jeremy A Schafer
    Prime Therapeutics LLC, Eagan, Minneasota 55121, USA
    J Manag Care Pharm 16:402-16. 2010
    ..Both agents use new mechanisms of action and add to the growing group of autoimmune biologics...
  18. ncbi request reprint Pharmacy students' views of managed care pharmacy and PBMS: should there be more exposure to managed care in the pharmacy curriculum?
    Amy L Pittenger
    University of Minnesota, College of Pharmacy, Mayo A 290, MMC 387, 420 Delaware St SE, Minneapolis, MN 55455, USA
    J Manag Care Pharm 16:346-54. 2010
    ..An issue frequently encountered is the limited amount of content in the pharmacy curriculum specific to managed care and the role and function of pharmacy benefit management companies (PBMs)...
  19. ncbi request reprint The emerging role of atypical pathogens in community-acquired pneumonia
    Patrick P Gleason
    College of Pharmacy, University of Minnesota, Minneapolis, USA
    Pharmacotherapy 22:2S-11S; discussion 30S-32S. 2002
    ....